Navina, a leader in AI-based clinical intelligence, announced the completion of a $55 million Series C funding round, bringing the total funding to $100 million. The funding round was led by Growth Equity at Goldman Sachs Alternatives, with participation from existing investors, including Vertex Ventures Israel, Grove Ventures, and ALIVE.
This investment will advance Navina’s expansion across the U.S. healthcare market, enhance its proprietary AI technology, and improve patient outcomes by bringing proactive clinical intelligence to every outpatient interaction.
Navina’s AI copilot rapidly established itself as the trusted solution for value-based care organizations, beginning with primary care and expanding to broader healthcare segments. And the platform serves over 10,000 healthcare professionals across 1,300 clinics and supports the care of more than three million patients. The company already secured partnerships with industry leaders including agilon health, InnovaCare Health, Millennium Physician Group, and Privia Health.
With healthcare transitioning toward value-based care, the need for accurate and timely clinical intelligence has become more critical than ever. However, fragmented data, inefficient manual workflows, and growing administrative burdens make it challenging for clinicians to deliver proactive, preventive patient care, resulting in poor clinical outcomes and high cost of care.
Navina provides clinicians and care teams with real-time and data-driven insights that improve the quality of care and financial outcomes. And Navina’s AI copilot surfaces clinical insights that support effective decision-making throughout the care continuum–from the back office to the point of care–while significantly reducing the administrative burden.
Navina also natively integrates into the clinician workflow, and maintains an impressive 86% weekly active usage rate and high trust in its AI recommendations within daily practice.
With this funding round, Navina will advance the development of its proprietary AI to ultimately become the definitive source of unified patient data that improves efficiency and care quality across the ecosystem from payers to providers. The company will expand its platform capabilities to further automate and optimize workflows from proactive population health management to effective point-of-care intervention.
KEY QUOTES:
“This investment is a powerful validation of Navina’s vision to improve patient outcomes and healthcare economics by breaking down data barriers with AI. We’re thrilled to partner with a best-in-class firm like Goldman Sachs, whose market leadership will be instrumental as we enter this pivotal growth phase and expand our market reach. With this additional capital, we will continue to accelerate AI innovation and revolutionize healthcare by making every patient interaction more empathic, personalized, and proactive.”
– Ronen Lavi, co-founder and CEO of Navina
“AI is rapidly transforming modern healthcare, and Navina stands at the forefront of that transformation – delivering real, measurable value to thousands of clinicians. Their deep integration into clinical workflows, unparalleled provider trust, and demonstrated ROI make them uniquely positioned to drive meaningful impact across the healthcare ecosystem. We believe Navina’s AI-powered platform is a game-changer, and we are excited to support their next stage of growth.”
– Irit Kahan, Managing Director in Growth Equity at Goldman Sachs Alternatives
